Maeva G.
- Country
- France
- Department
- Gastro-enterology, Endoscopy and Hepatic Diseases
Research Overview
- Phase 3 Evaluation of Pegozafermin Efficacy and Safety in Metabolic Dysfunction-Associated Steatohepatitis with Compensated Cirrhosis
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Lanifibranor in Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages F2/F3
- Evaluation of Pegozafermin Efficacy and Safety in Patients with Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: A Phase 3 Clinical Trial
Data & Insights
Has run more than one trial at 65 of 137 partner sites.
Specializations
Liver Disease Expertise
This investigator specializes in treating complex hepatic conditions, with particular focus on non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatotic liver disease (MASH).
- Advanced Liver Fibrosis Management
- NASH/MASH Treatment Approaches
- Hepatic Disease Progression
Their work encompasses various stages of liver fibrosis, particularly focusing on F2/F3 stage patients.
Metabolic Health
The investigator's expertise extends to metabolic liver disorders and their relationship with systemic metabolic dysfunction.
- Metabolic Disease Mechanisms
- Liver-Metabolic Interface
- Non-Cirrhotic Liver Conditions
Their therapeutic approach addresses both hepatic and metabolic aspects of liver disease.
Clinical Assessment
The investigator specializes in liver histology evaluation and assessment of therapeutic responses in chronic liver conditions.
- Histological Assessment
- Disease Resolution Monitoring
- Long-term Treatment Outcomes
Their expertise includes evaluation of liver biopsy results and clinical outcome measurements.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.